Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Almac, a provider of services to pharmaceutical and biotech sectors, has expanded its biocatalysis business with the launch of selectAZyme.
Subscribe to our email newsletter
Almac has implemented biocatalytic technology for metabolite synthesis, isolation and structural identification.
Metabolite synthesis is another tool within selectAZyme’s service providing access to both oxidative and glycosylated products.
Almac has developed recombinant P450 technology for accessing metabolites at mg to 100s grams.
In addition, Almac can also supply radiolabelled versions of these metabolites using in-house Isotope Chemistry group.
The selectAZyme service complements Almac’s speciality capabilities, including radiolabelling, polymorph and solid form optimisation, and peptide and protein synthesis.
These services are all part of Almac’s Drug Discovery Services, including API and Drug Product Development and GMP Manufacture.
Biocatalysis head Tom Moody said Almac provides a diverse, A-Z range of enzymes including reductases, transaminases, hydrolases, nitrilases and many others.
"Almac enzymes are used in the A-Z of applications from medicinal chemistry to full production and in the manufacture of specialty chemicals." Moody said.